Leerink downgraded Eli Lilly (LLY) to Market Perform from Outperform with a $715 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Morning Movers: Apple adds to yesterday’s gains, Trump calls out Intel CEO
- Video: Apple rises on U.S. investment, Trump calls for Intel CEO to quit
- LLY Earnings: Eli Lilly Sinks Despite Strong Q2 Beats
- Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
- Eli Lilly raises FY25 EPS view to $21.75-$23.00 from $20.78-$22.28